

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



8

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68, C07K 16/8</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/12758</b> <b>(43) International Publication Date:</b> 9 March 2000 (09.03.00)
<b>(21) International Application Number:</b> PCT/US99/19655 <b>(22) International Filing Date:</b> 1 September 1999 (01.09.99)  <b>(30) Priority Data:</b> 60/098,880 2 September 1998 (02.09.98) US  <b>(71) Applicant (for all designated States except US):</b> DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SALCEDA, Susana [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). CAFFERKEY, Robert [IE/US]; Apartment 218, 350 Elan Village Lane, San Jose, CA 95134 (US).  <b>(74) Agents:</b> LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).		<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS		
<b>(57) Abstract</b> <p>The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**A NOVEL METHOD OF DIAGNOSING,  
MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS**

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed  
5 assays for detecting, diagnosing, monitoring, staging,  
prognosticating, imaging and treating various cancers,  
particularly gynecologic cancer including ovarian, uterine  
endometrial and breast cancer, and lung cancer.

**BACKGROUND OF THE INVENTION**

10 The American Cancer Society has estimated that over  
560,000 Americans will die this year from cancer. Cancer is  
the second leading cause of death in the United States,  
exceeded only by heart disease. It has been estimated that  
over one million new cancer cases will be diagnosed in 1999  
15 alone.

In women, gynecologic cancers account for more than one-  
fourth of the malignancies.

Of the gynecologic cancers, breast cancer is the most  
common. According to the Women's Cancer Network, 1 out of  
20 every 8 women in the United States is at risk of developing  
breast cancer, and 1 out of every 28 women are at risk of  
dying from breast cancer. Approximately 77% of women  
diagnosed with breast cancer are over the age of 50.  
However, breast cancer is the leading cause of death in women  
25 between the ages of 40 and 55.

Carcinoma of the ovary is another very common  
gynecologic cancer. Approximately one in 70 women will  
develop ovarian cancer during her lifetime. An estimated  
14,500 deaths in 1995 resulted from ovarian cancer. It causes  
30 more deaths than any other cancer of the female reproductive  
system. Ovarian cancer often does not cause any noticeable

symptoms. Some possible warning signals, however, are an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40; rarely there will be abnormal vaginal bleeding.

5 Periodic, complete pelvic examinations are important; a Pap test does not detect ovarian cancer. Annual pelvic exams are recommended for women over 40.

Also common in women is endometrial cancer or carcinoma of the lining of the uterus. According to the Women's Cancer

10 Center endometrial cancer accounts for approximately 13% of all malignancies in women. There are about 34,000 cases of endometrial cancer diagnosed in the United States each year.

Uterine sarcoma is another type of uterine malignancy much more rare as compared to other gynecologic cancers. In

15 uterine sarcoma, malignant cells start growing in the muscles or other supporting tissues of the uterus. Sarcoma of the uterus is different from cancer of the endometrium, a disease in which cancer cells start growing in the lining of the uterus. This uterine cancer usually begins after menopause.

20 Women who have received therapy with high-dose X-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus. These X-rays are sometimes given to women to stop bleeding from the uterus.

Lung cancer is the second most prevalent type of cancer

25 for both men and women in the United States and is the most common cause of cancer death in both sexes. Lung cancer can result from a primary tumor originating in the lung or a secondary tumor which has spread from another organ such as the bowel or breast. Primary lung cancer is divided into

30 three main types; small cell lung cancer; non-small cell lung cancer; and mesothelioma. Small cell lung cancer is also called "Oat Cell" lung cancer because the cancer cells are a distinctive oat shape. There are three types of non-small cell lung cancer. These are grouped together because they behave

35 in a similar way and respond to treatment differently to small

- 3 -

cell lung cancer. The three types are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Squamous cell cancer is the most common type of lung cancer. It develops from the cells that line the airways. Adenocarcinoma  
5 also develops from the cells that line the airways. However, adenocarcinoma develops from a particular type of cell that produces mucus (phlegm). Large cell lung cancer has been thus named because the cells look large and rounded when they are viewed under a microscope. Mesothelioma is a rare type of  
10 cancer which affects the covering of the lung called the pleura. Mesothelioma is often caused by exposure to asbestos.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating each of these types of cancer are of critical importance to the outcome of the patient. In all  
15 cases, patients diagnosed early in development of the cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with a cancer which has metastasized. New diagnostic methods which are more sensitive and specific for early detection of various  
20 types of cancer are clearly needed.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, in vivo imaging and treating selected cancers including, but not limited to, gynecologic cancers such as ovarian, breast  
25 endometrial and/or uterine cancer, and lung cancer via detection of a Cancer Specific Genes (CSGs). Nine CGSs have been identified and refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9.  
30 In the alternative, what is meant by the nine CSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4,

5, 6, 7, 8 or 9. Fragments of the CSGs such as those depicted in SEQ ID NO:10, 11, 12, 13 or 14 can also be detected.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the selected cancer. For the purposes of this invention, by "selected cancer" it is meant to include gynecologic cancers such as ovarian, breast, endometrial and uterine cancer, and lung cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having a selected cancer which is not known to have metastasized by identifying a human patient suspected of having a selected cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient

versus the normal human control is associated with a cancer which has metastasized.

Also provided by the invention is a method of staging selected cancers in a human patient by identifying a human  
5 patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid  
10 type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring selected  
15 cancers in patients for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or  
20 bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

25 Further provided is a method of monitoring the change in stage of selected cancers in humans having such cancer by looking at levels of CSG. The method comprises identifying a human patient having a selected cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from  
30 such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a  
35 cancer which is progressing and a decrease in the levels of

CSG is associated with a cancer which is regressing or in remission.

Further provided are antibodies against CSG or fragments of such antibodies which can be used to detect or image localization of CSG in a patient for the purpose of detecting or diagnosing selected cancers. Such antibodies can be polyclonal or monoclonal, or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a CSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating selected



- 7 -

cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by levels of CSG as used herein is levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by levels of CSG as used herein is levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels of the gene comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. Fragments of CSGs such as those depicted in SEQ ID NO: 10, 11, 12, 13 and 14 can also be detected. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of CSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of selected cancers. What is meant by "selected cancers" as used herein is a gynecologic cancer such as ovarian, breast, endometrial or uterine cancer, or lung case.

Any of the 9 CSGs can be measured alone in the methods of the invention, or all together or any combination thereof. However, for methods relating to gynecologic cancers including ovarian, breast, endometrial and uterine cancer, it is preferred that levels of CSG comprising SEQ ID NO:1 or a fragment thereof be determined. Exemplary fragments of this CSG which can be detected are depicted in SEQ ID NO: 10, 11, 12, and 13. For methods relating to lung cancer and gynecologic cancers including ovarian, endometrial and uterine, it is preferred that levels of CSG comprising SEQ ID NO:2 or 9 be determined. Fragments of this CSG such as that depicted in SEQ ID NO:14 can also be detected. For methods relating to ovarian cancer, determination of levels of CSG comprising SEQ ID NO:3 is also preferred.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

### **Diagnostic Assays**

The present invention provides methods for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the presence of a selected cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastases of selected cancers in a patient having a selected cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having a selected cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of ovarian cancer, patients are typically diagnosed with ovarian cancer following surgical staging and monitoring of CA125 levels. Traditional detection methods are also available and well known for other selected cancers which can be diagnosed by determination of CSG levels in a patient.

In the present invention, determining the presence of CSG levels in cells, tissues or bodily fluid, is particularly useful for discriminating between a selected cancer which has not metastasized and a selected cancer which has metastasized.

5 Existing techniques have difficulty discriminating between cancers which have metastasized and cancers which have not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels  
10 measured in such cells, tissues or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is CSG in serum, this level is preferably compared with the level of CSG in serum  
15 of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with a cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating  
20 the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily  
25 fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may also include samples from  
30 a human patient that is determined by reliable methods to have a selected cancer which has not metastasized.

### **Staging**

The invention also provides a method of staging selected cancers in human patients. The method comprises identifying  
35 a human patient having a selected cancer and analyzing a

sample of cells, tissues or bodily fluid from such human patient for CSG. Then, the method compares CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

#### 10 **Monitoring**

Further provided is a method of monitoring selected cancers in humans for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of selected cancers in humans having such cancers. The method comprises identifying a human patient having a selected cancer; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

## 5 **Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include  
10 radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein  
15 in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds  
20 specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to CSG is  
25 incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds  
30 to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG.  
35 Unattached reporter antibody is then washed out. Reagents for

peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to CSG attached to a solid support and labeled CSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods may be used to detect CSG mRNA as a marker for selected cancers. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of the various selected malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon

or plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

5 Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be

10 done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

15 Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.

20 First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on

25 the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or

30 subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue

35 extracts (homogenates or solubilized tissue) such as from

tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.

5 ***In Vivo Antibody Use***

Antibodies against CSG can also be used *in vivo* in patients suspected of suffering from a selected cancer including lung cancer or gynecologic cancers such as ovarian, breast, endometrial or uterine cancer. Specifically, 10 antibodies against a CSG can be injected into a patient suspected of having a selected cancer for diagnostic and/or therapeutic purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use 15 in the radioimmunoscentographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. 20 Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSGs can be used in a similar manner. Labeled antibodies against a CSG can be 25 injected into patients suspected of having a selected cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or 30 Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can used in magnetic resonance imaging (MRI). 35 Localization of the label permits determination of the spread



of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with a selected cancer, injection of an antibody against a CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. *Cell* 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares *Cancer Supplement* 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against CSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments. The exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

**EXAMPLES****Example 1:**

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte  
5 Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

The CLASP performs the following steps: selection of highly expressed organ specific genes based on the abundance  
10 level of the corresponding EST in the targeted organ versus all the other organs; analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease. Selection of the candidates demonstrating component  
15 ESTs were exclusively or more frequently found in tumor libraries. The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the CSGs selection.

20 **Table 1: CSG Sequences**

	SEQ ID NO:	Clone ID	Gene ID
	1	16656542	234617
	2	1283171	332459
	3	1649377	481154
25	4	236044H1	none assigned
	5	none assigned	255687
	6	none assigned	251313
	7	none assigned	12029
	8	none assigned	251804

30

The following examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail.

Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

### Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene for every example in normal and cancer tissue were evaluated. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700

Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

**Measurement of Ovr110; Clone ID16656542; Gene ID 234617 (SEQ ID NO:1, 10, 11, 12 or 13)**

The absolute numbers depicted in Table 2 are relative levels of expression of Ovr110 (SEQ ID NO:1 or a fragment thereof as depicted in SEQ ID NO:10, 11, 12, or 13) in 12 normal different tissues. All the values are compared to normal stomach (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 2: Relative Levels of Ovr110 Expression in Pooled Samples**

Tissue	NORMAL
colon	0.00
endometrium	8.82
kidney	7.19
liver	0.36
ovary	1.19
pancreas	21.41
prostate	2.79
small intestine	0.03
spleen	0.00
00000000000000stoma	1.00
testis	8.72
uterus	0.93

The relative levels of expression in Table 2 show that Ovr110 is expressed at comparable levels in most of the normal tissues analyzed. Pancreas, with a relative expression level of 21.41, endometrium (8.82), testis (8.72), and kidney (7.19) are the only tissues expressing high levels of Ovr110 mRNA.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of Ovr110 in 73 pairs of matching samples. All the values are compared to normal stomach (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 15 unmatched cancer samples (from ovary and mammary gland) and 14 unmatched normal samples (from ovary and mammary gland) were also tested.

10 **Table 3: Relative Levels of Ovr110 Expression in Individual Samples**

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
Ovr103X	Ovary 1	86.22	0.53	
Ovr10400	Ovary 2	168.31		
15 Ovr1157	Ovary 3	528.22		
Ovr63A	Ovary 4	1.71		
Ovr7730	Ovary 5	464.65		
Ovr10050	Ovary 6	18.32		
Ovr1028	Ovary 7	7.78		
20 Ovr1118	Ovary 8	0.00		
Ovr130X	Ovary 9	149.09		
Ovr638A	Ovary 10	3.14		
OvrA1B	Ovary 11	21.26		
OvrA1C	Ovary 12	1.83		
25 OvrC360	Ovary 13	0.52		
Ovr18GA	Ovary 14			1.07
Ovr20GA	Ovary 15			1.88
Ovr25GA	Ovary 16			2.52
Ovr206I	Ovary 17			2.51
30 Ovr32RA	Ovary 18			3.01

- 20 -

5	Ovr35GA	Ovary 19			5.17
	Ovr40G	Ovary 20			0.45
	Ovr50GB	Ovary 21			2.69
	OvrC087	Ovary 22			0.47
	OvrC179	Ovary 23			1.46
10	OvrC004	Ovary 24			4.99
	OvrC007	Ovary 25			13.36
	OvrC109	Ovary 26			6.61
	MamS516	Mammary Gland 1	16.39	13.74	
	MamS621	Mammary Gland 2	826.70	4.60	
15	MamS854	Mammary Gland 3	34.60	18.30	
	Mam59X	Mammary Gland 4	721.57	27.00	
	MamS079	Mammary Gland 5	80.73	5.10	
	MamS967	Mammary Gland 6	6746.90	72.80	
	MamS127	Mammary Gland 7	7.00	20.00	
20	MamB011X	Mammary Gland 8	1042.00	29.00	
	Mam12B	Mammary Gland 9	1342.00		
	Mam82XI	Mammary Gland 10	507.00		
	MamS123	Mammary Gland 11	24.85	4.24	
	MamS699	Mammary Gland 12	84.74	5.54	
	MamS997	Mammary Gland 13	482.71	11.84	
	Mam162X	Mammary Gland 14	15.73	10.59	

- 21 -

	MamA06X	Mammary Gland 15	1418.35	8.20	
	Mam603X	Mammary Gland 16	294.00		
	Mam699F	Mammary Gland 17	567.40	86.60	
	Mam12X	Mammary Gland 18	425.00	31.00	
5	MamA04	Mammary Gland 19			2.00
	Mam42DN	Mammary Gland 20	46.05	31.02	
	Utr23XU	Uterus 1	600.49	27.95	
	Utr85XU	Uterus 2	73.52	18.83	
	Utr135XO	Uterus 3	178.00	274.00	
10	Utr141XO	Uterus 4	289.00	26.00	
	CvxNKS54	Cervix 1	2.47	0.61	
	CvxKS83	Cervix 2	1.00	2.00	
	CvxNKS18	Cervix 3	1.00	0.00	
	CvxNK23	Cervix 4	5.84	14.47	
15	CvxNK24	Cervix 5	20.32	33.13	
	End68X	Endometrium 1	167.73	544.96	
	End8963	Endometrium 2	340.14	20.89	
	End8XA	Endometrium 3	1.68	224.41	
	End65RA	Endometrium 4	303.00	5.00	
20	End8911	Endometrium 5	1038.00	74.00	
	End3AX	Endometrium 6	6.59	1.69	
	End4XA	Endometrium 7	0.43	15.45	

	End5XA	Endometrium 8	17.81	388.02	
	End10479	Endometrium 9	1251.60	31.10	
	End12XA	Endometrium 10	312.80	33.80	
	Kid107XD	Kidney 1	2.68	29.65	
5	Kid109XD	Kidney 2	81.01	228.33	
	Kid10XD	Kidney 3	0.00	15.30	
	Kid6XD	Kidney 4	18.32	9.06	
	Kid11XD	Kidney 5	1.38	20.75	
	Kid5XD	Kidney 6	30.27	0.19	
10	Liv15XA	Liver 1	0.00	0.45	
	Liv42X	Liver 2	0.81	0.40	
	Liv94XA	Liver 3	12.00	2.16	
	Lng LC71	Lung 1	5.45	3.31	
	LngAC39	Lung 2	1.11	0.00	
15	LngBR94	Lung 3	4.50	0.00	
	LngSQ45	Lung 4	15.03	0.76	
	LngC20X	Lung 5	0.00	1.65	
	LngSQ56	Lung 6	91.77	8.03	
	ClnAS89	Colon 1	0.79	7.65	
20	ClnC9XR	Colon 2	0.03	0.00	
	ClnRC67	Colon 3	0.00	0.00	
	ClnSG36	Colon 4	0.81	0.35	
	ClnTX89	Colon 5	0.00	0.00	
	ClnSG45	Colon 6	0.00	0.06	
25	ClnTX01	Colon 7	0.00	0.00	
	Pan77X	Pancreas 1	0.89	2.62	
	Pan71XL	Pancreas 2	3.99	0.12	
	Pan82XP	Pancreas 3	59.92	28.44	
	Pan92X	Pancreas 4	17.21	0.00	



	StoAC93	Stomach 1	7.54	6.43	
	StoAC99	Stomach 2	19.49	3.19	
	StoAC44	Stomach 3	3.62	0.37	
	SmI21XA	Small Intestine 1	0.00	0.00	
5	SmIH89	Small Intestine 2	0.00	0.00	
	Bld32XK	Bladder 1	0.00	0.21	
	Bld46XK	Bladder 2	0.36	0.32	
	BldTR17	Bladder 3	0.28	0.00	
	Tst39X	Testis	11.24	2.24	
10	Pro84XB	Prostate 1	2.60	24.30	
	Pro90XB	Prostate 2	1.40	2.00	

0.00= Negative

Table 2 and Table 3 represent a combined total of 187 samples in 16 different tissue types. In the analysis of matching samples, the higher levels of expression were in mammary gland, uterus, endometrium and ovary, showing a high degree of tissue specificity for the gynecologic tissues. Of all the samples different than those mentioned before analyzed, only a few samples (Kid109XD, LngSQ56, and Pan82XP) showed high levels of expression of Ovr110.

Furthermore, the level of mRNA expression was compared in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Ovr110 in 15 of 16 mammary gland cancer tissues compared with their respective normal adjacent (mammary gland samples MamS516, MamS621, MamS854, Mam59X, MamS079, MamS967, MamB011X, MamS123, MamS699, MamS997, Mam162X, MamA06X, Mam699F, Mam12X, and Mam42DN).

There was overexpression in the cancer tissue for 94% of the mammary gland matching samples tested.

For uterus, Ovr110 is overexpressed in 3 of 4 matching samples (uterus samples Utr23XU, Utr85XU, and Utr141XO). There  
5 was overexpression in the cancer tissue for 75% of the uterus matching samples analyzed.

For endometrium, Ovr110 is overexpressed in 6 of 10 matching samples (endometrium samples End8963, End65RA, End8911, End3AX, End10479, and End12XA). There was  
10 overexpression in the cancer tissue for 60% of the endometrium matching samples.

For ovary, Ovr110 shows overexpression in 1 of 1 matching sample. For the unmatched ovarian samples, 8 of 12 cancer samples show expression values of Ovr110 higher than  
15 the median (2.52) for the normal unmatched ovarian samples. There was overexpression in the cancer tissue for 67% of the unmatched ovarian samples.

Altogether, the level of tissue specificity, plus the mRNA overexpression in most of the matching samples tested are  
20 indicative of Ovr110 (including SEQ ID NO:1, 10, 11, 12 or 13) being a diagnostic marker for gynecologic cancers, specifically, mammary gland or breast, uterine, ovarian and endometrial cancer.

**Measurement of Ovr114; Clone ID1649377; Gene ID 481154 (SEQ  
25 ID NO:3)**

The numbers depicted in Table 4 are relative levels of expression in 12 normal tissues of Ovr114 compared to pancreas (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue  
30 from different individuals.

**Table 4: Relative Levels of Ovr114 Expression in Pooled Samples**

Tissue	Normal
Colon	2.3
Endometrium	7.6
Kidney	0.5
Liver	0.6
Ovary	5.2
Pancreas	1.0
Prostate	2.1
Small Intestine	1.3
Spleen	2.4
Stomach	1.5
Testis	15.8
Uterus	8.8

The relative levels of expression in Table 4 show that Ovr114 mRNA expression is detected in all the pools of normal tissues analyzed.

The tissues shown in Table 4 are pooled samples from 20 different individuals. The tissues shown in Table 5 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 4 cannot be directly compared to the values shown in Table 5.

The numbers depicted in Table 5 are relative levels of 25 expression of Ovr114 compared to pancreas (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 5: Relative Levels of Ovr114 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	17.04		3.93
Ovary 2	OvrG021SPI/SN2	Papillary serous adenocarcinoma	1.62		4.34
Ovary 3	OvrG010SP/SN	Papillary serous adenocarcinoma	0.50		1.12
Ovary 4	OvrA081F/A082D	Mucinous tumor, low malignant potential		0.84	0.96
Ovary 5	OvrA084/A086	Mucinous tumor, grade G-B, borderline		5.24	6.00
Ovary 6	Ovr14604A1C	Serous cystadenofibroma, low malignancy		5.33	
Ovary 7	Ovr14638A1C	Follicular cysts, low malignant potential		8.11	
Ovary 8	Ovr10400	Papillary serous adenocarcinoma, G2	13.27		
Ovary 9	Ovr11570	Papillary serous adenocarcinoma	106.08		
Ovary 10	Ovr10050	Papillary serous endometrial carcinoma	77.04		
Ovary 11	Ovr10280	Ovarian carcinoma	14.78		
Ovary 12	Ovr14603A1D	Adenocarcinoma	22.23		

5

10

- 27 -

Ovary 13	Ovr9410C360	Endometrioid adenocarcinoma	4.74		
Ovary 14	Ovr1305X	Papillary serous adenocarcinoma	96.49		
Ovary 15	Ovr7730	Papillary serous adenocarcinoma	8.40		
Ovary 16	Ovr988Z	Papillary serous adenocarcinoma	6.40		
Ovary 17	Ovr9702C018GA	Normal Cystic			12.06
Ovary 18	Ovr2061	Normal left atrophic, small cystic			10.11
Ovary 19	Ovr9702C020GA	Normal-multiple ovarian cysts			12.70
Ovary 20	Ovr9702C025GA	Normal-hemorrhage CL cysts			22.09
Ovary 21	Ovr9701C050GB	Normal-multiple ovarian cysts			9.01
Ovary 22	Ovr9701C087RA	Normal-small follicle cysts			1.86
Ovary 23	Ovr9702C032RA				7.81
Ovary 24	Ovr9701C109RA	Normal			1.50
Ovary 25	Ovr9411C057R	Benign large endometriotic cyst			5.22
Ovary 26	Ovr9701C179a	Normal			3.09
Ovary 27	Ovr14610	Serous cystadenofibroma, no malignancy			3.53
Ovary 28	Ovr9701C035GA	Normal			6.32

5

10

15

- 28 -

Ovary 29	Ovr9702C007RA	Normal				0
Ovary 30	Ovr9701C087RA	Normal-small follicle cysts				1.97
Ovary 31	Ovr9411C109	Normal				9.49
Ovary 32	Ovr9701C177a	Normal-cystic follicles				3.85
Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	1.30			0.70
Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	1.83			11.90
Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	13.32			7.76
Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	3.62			3.34
Mammary Gland 1	Mam00042D01/N01		3.13			0.76
Mammary Gland 2	MamS99-522A/B		4.45			0.45
Mammary Gland 3	Mam1620F/1621F		0.74			1.91
Mammary Gland 4	Mam4003259a/g		3.48			2.00
Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	46.96			11.96
Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	20.02			5.90
Uterus 3	Utr13590/13580	Tumor/NAT	10.23			7.74
Uterus 4	Utr14170/14180	Malignant tumor/NAT	7.52			4.92

5

10

15

20

- 29 -

Cervix 1	CvxVNM00083/83	Keratinizing squamous cell carcinoma	5.47	14.31
Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	4.99	3.99
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	10.14	14.22
Bladder 1	Bld665T/664T		1.43	4.03
Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	1.15	0.99
Kidney 1	Kid4003710C/F		0.03	0.35
Kidney 2	Kid1242D/1243D		1.61	0.14
Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	2.44	5.73
Lung 2	Lng8890A/8890B	Cancer/NAT	1.11	5.19
Lung 3	Lng9502C109R/10R		1.99	0.80
Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.67	1.07
Liver 2	LivVNM00175/175	Cancer/NAT	15.46	2.85
Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	2.83	0.70
Skin 2	Skn4005287A1/B2		0.91	4.02
Small Int. 1	SmI9802H008/009		0.87	0.82
Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT	0.81	1.22
Stomach 2	StoS9822539A/B	Adenocarcinoma/NAT	1.22	1.39

5

10

15

- 30 -

Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor	0.47		0.35
Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	2.39		2.61
Prostate 2	Pro1094B/1095B		0.10		0.38
Pancreas 1	Pan776p/777p	Tumor/NAT	2.39		0.52
Pancreas 2	Pan824p/825p	Cystic adenoma	1.66		1.22
Testis 1	Tst239X/240X	Tumor/NAT	1.24		1.72
Colon 1	Cln9706c068ra/69ra	Adenocarcinoma/NAT	0.38		0.65
Colon 2	Cln4004732A7/B6	Adenocarcinoma/NAT	0.44		1.26
Colon 3	Cln4004695A9/B8		1.94		1.53
Colon 4	Cln9612B006/005	Asc. Colon, Cecum, adenocarcinoma	3.38		1.10
Colon 5	Cln9704C024R/25R	Adenocarcinoma/NAT	1.66		2.77

5

10



- 31 -

Table 4 and Table 5 represent a combined total of 129 samples in 17 human tissue types. Among 117 samples in Table 5 representing 16 different tissues high levels of expression are seen only in ovarian cancer samples. The median expression of Ovr114 is 14.03 (range: 0.5 - 106.08) in ovarian cancer and 4.34 (range: 0 - 22.09) in normal ovaries. In other words, the median expression levels of Ovr114 in cancer samples is increased 3.5 fold as compared with that of the normal ovarian samples. Five of 12 ovarian cancers (42%) showed increased expression relative to normal ovary (with 95% specificity). The median expression of Ovr114 in other gynecologic cancers is 4.99, and 2 out of 15 samples showed expression levels comparable with that in ovarian cancer. The median of the expression levels of Ovr114 in the rest of the cancer samples is 1.24, which is more than 11 fold less than that detected in ovarian cancer samples. No individual showed an expression level comparable to that of ovarian cancer samples (except Liver 2; LivVNM00175/175).

The 3.5 fold increase in expression in 42% of the individual ovarian cancer samples and no compatible expression in other non-gynecologic cancers is indicative of Ovr114 being a diagnostic marker for detection of ovarian cancer cells. It is believed that the Ovr114 marker may also be useful in detection of additional gynecologic cancers.

**Measurement of Ovr115; Clone ID1283171; Gene ID 332459 (SEQ ID NO:2 or 14)**

The numbers depicted in Table 6 are relative levels of expression Ovr115 compared to their respective calibrators. The numbers are relative levels of expression in 12 normal tissues of ovaries compared to Testis (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue from different individuals.

Table 6: Relative Levels of Ovr115 Expression in Pooled Samples

Tissue	Normal
Colon	858.10
Endometrium	12.34
Kidney	3.76
Liver	0.00
Ovary	0.43
Pancreas	0.00
Prostate	8.91
Small Intestine	62.25
Spleen	0.00
Stomach	37.53
Testis	1.00
Uterus	47.67

The relative levels of expression in Table 6 show that Ovr115 mRNA expression is detected in all the 12 normal tissue pools analyzed.

The tissues shown in Table 6 are pooled samples from 20 different individuals. The tissues shown in Table 7 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 6 cannot be directly compared to the values shown in Table 7.

The numbers depicted in Table 7 are relative levels 25 of expression of Ovr115 compared to testis (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 7: Relative Levels of Ovr115 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	193.34		0.24
Ovary 3	OvrG021SPI/SN2	Papillary serous adenocarcinoma	0.38		0.31
Ovary 4	OvrG010SP/SN	Papillary serous adenocarcinoma	231.25		0.45
Ovary 2	OvrA084/A086	Mucinous tumor, grade G-B, borderline		143.34	16.65
Ovary 5	OvrA081F/A082D	Mucinous tumor, low malignant potential		314.13	0
Ovary 19	Ovr14604A1C	Serous cystadenofibroma, low malignancy		299.87	
Ovary 26	Ovr14638A1C	Follicular cysts, low malignant potential		1278.32	
Ovary 6	Ovr10400	Papillary serous adenocarcinoma, G2	144.25		
Ovary 22	Ovr9410C360	Endometrioid adenocarcinoma	0.29		
Ovary 23	Ovr1305X	Papillary serous adenocarcinoma	157.41		
Ovary 27	Ovr7730	Papillary serous adenocarcinoma	340.04		
Ovary 28	Ovr988Z	Papillary serous adenocarcinoma	464.75		

5

10

- 34 -

Ovary 7	Ovr11570	Papillary serous adenocarcinoma	432.07		
Ovary 8	Ovr10050	Papillary serous endometrial carcinoma	74.23		
Ovary 9	Ovr10280	Ovarian carcinoma	1408.79		
Ovary 10	Ovr14603A1D	Adenocarcinoma	0.00		
Ovary 11	Ovr9702C018GA	Normal Cystic			0.16
Ovary 12	Ovr2061	Normal left atrophic, small cystic			0.00
Ovary 13	Ovr9702C020GA	Normal-multiple ovarian cysts			0.00
Ovary 14	Ovr9702C025GA	Normal-hemorrhage CL cysts			0.00
Ovary 15	Ovr9701C050GB	Normal-multiple ovarian cysts			0.91
Ovary 16	Ovr9701C087RA	Normal-small follicle cysts			0.00
Ovary 17	Ovr9702C032RA				0.28
Ovary 18	Ovr9701C109RA	Normal			0.00
Ovary 20	Ovr9411C057R	Benign large endometriotic cyst			38.87
Ovary 21	Ovr9701C179a	Normal			0.08
Ovary 24	Ovr14610	Serous cystadenofibroma, no malignancy			0.00
Ovary 25	Ovr9701C035GA	Normal			0.00
Ovary 29	Ovr9702C007RA	Normal			0.00

5

10

15

- 35 -

Ovary 30	Ovr9701C087RA	Normal-small follicle cysts			0.00
Ovary 31	Ovr9411C109	Normal			0.00
Ovary 32	Ovr9701C177a	Normal-cystic follicles			0.00
Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	39.95		13.60
Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	140.37		22.67
Uterus 3	Utr13590/1358)	Tumor/NAT	16.45		32.50
Uterus 4	Utr14170/14180	Malignant tumor/NAT	288.52		5.29
Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	2.61		6.24
Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	2.10		49.40
Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	480.77		19.22
Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	322.07		31.08
Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	38.81		7.36
Lung 2	Lng8890A/8890B	Cancer/NAT	690.12		14.71
Lung 3	Lng9502C109R/10R		1756.90		2.86
Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	10.56		0.00
Skin 2	Skn4005287A1/B2		331.30		47.23
Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	14.64		4.39

5

10

15

Prostate 2	Pro1094B/1095B			0.09		2.54
Bladder 1	Bld665T/664T			404.56		90.20
Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT		77.35		177.37
Kidney 1	Kid4003710C/F			0.17		12.72
Kidney 2	Kid1242D/1243D			0.00		13.74
Mammary Gland 1	Mam1620F/1621F			0.27		0.12
Mammary Gland 2	Mam4003259a/g			5.71		0.00
Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT		0.14		0.69
Liver 2	LivVNM00175/175	Cancer/NAT		0.00		0.00
Small Int. 1	SmI9802H008/009			128.44		151.38
Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT		303.01		116.72
Stomach 2	StoS9822539A/B	Adenocarcinoma/NAT		24.12		17.76
Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor		0.00		9.10
Pancreas 1	Pan776p/777p	Tumor/NAT		0.00		0.43
Pancreas 2	Pan824p/825p	Cystic adenoma		0.00		3.17
Testis 1	Tst239X/240X	Tumor/NAT		24.05		1.37
Colon 1	Cln9706c068ra/69ra	Adenocarcinoma/NAT		605.60		169.77
Colon 2	Cln4004732A7/B6	Adenocarcinoma/NAT		367.20		281.32

5

10

15

20

- 37 -

Colon 3	Cln4004695A9/B8		316.15		295.77
Colon 4	Cln9612B006/005	Asc. Colon. Cecum, adenocarcinoma	820.89		543.52
Colon 5	Cln9704C024R/25R	Adenocarcinoma/NAT	161.18		150.07
Cervix 1	CvxVNM00083/83	Keratinizing squamous cell carcinoma	738.17		1195.88
Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	1473.04		1229.80
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	2877.48		1275.02

- 38 -

Table 6 and Table 7 represent a combined total of 129 samples in 17 human tissue types. Comparisons of the level of mRNA expression in ovarian cancer samples and the normal adjacent tissue from the same individuals or normal tissues from other individuals are shown in Table 7. Ovr115 was expressed at higher levels in 9 of 12 cancer tissues (75%), relative to the maximum level detected in all 21 normal or normal adjacent ovarian samples. All 4 of 4 (100%) ovarian tumors with borderline malignancy had elevated Ovr115 expression. The median expression in ovarian cancers (including the ones with borderline malignancy) was 212.30 while the median expression in normal ovaries was 0. When compared with their own normal adjacent tissue samples, expression levels of Ovr115 were also elevated in 3 of 3 (100%) lung cancers, 3 of 4 (75%) uterus cancers and 2 of 4 (50%) endometrial cancers.

The relatively high expression levels of Ovr115 in ovarian and other selected cancer samples is indicative of Ovr115 being a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer.

A homolog of Ovr115 has also been identified in public data base; g2597613 as gi|2507612|gb|U75329.1|HSU75329 Human serine protease mRNA, complete CDS. This homolog is depicted herein as SEQ ID NO:9. It is believed that SEQ ID NO:9 or the protein encoded thereby (SEQ ID NO:15) may also be useful as a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer in human patients.



- 39 -

**What is claimed is:**

1. A method for diagnosing the presence of a selected cancer in a patient comprising:

(a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and

5 (b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CSG in said patient versus normal human control is associated with the presence of a selected cancer.

10 2. A method of diagnosing metastases of a selected cancer in a patient comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

(b) measuring CSG levels in a sample of cells, tissues,  
15 or bodily fluid from said patient; and

(c) comparing the measured CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer  
20 which has metastasized.

3. A method of staging a selected cancer in a patient having the selected cancer comprising:

(a) identifying a patient having the selected cancer;

(b) measuring CSG levels in a sample of cells, tissue,  
25 or bodily fluid from said patient; and

(c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control sample, wherein an increase in measured CSG levels in said patient versus the normal human control is associated with a  
30 cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

- 40 -

4. A method of monitoring a selected cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

(b) periodically measuring levels of CSG in samples of  
5 cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the  
10 normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of a selected cancer in a patient comprising:

(a) identifying a patient having a selected cancer;

15 (b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the  
20 periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG  
25 comprises SEQ ID NO:1, 10, 11, 12 or 13 and the selected cancer is a gynecologic cancer selected from the group consisting of breast, ovarian, endometrial and uterine cancer.

7. The method of claim 1, 2, 3, 4 or 5 wherein the CSG  
30 comprises SEQ ID NO:2, 9 or 14 and the selected cancer is lung cancer or a gynecologic cancer selected from the group consisting of ovarian, endometrial and uterine cancer.

- 41 -

8. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14 and the selected cancer is ovarian cancer.

9. An antibody against a CSG wherein said CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14.

5 10. A method of imaging a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

11. The method of claim 10 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10 12. A method of treating a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

13. The method of claim 12 wherein the antibody is conjugated to a cytotoxic agent.

## SEQUENCE LISTING

<110> Salceda, Susana  
Sun, Yongming  
Recipon, Herve  
Cafferkey, Robert  
DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,  
IMAGING AND TREATING VARIOUS CANCERS

<130> DEX-0043

<140>

<141>

<150> 60/098,880

<151> 1998-09-02

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 2587

<212> DNA

<213> Homo sapiens

<400> 1

```
ggaaggcagc gggcagctcc actcagccag taccagata cgctgggaac cttccccagc 60
catggcttcc ctggggcaga tcctcttctg gagcataatt agcatcatca ttattctggc 120
tgagcaatt gcactcatca ttggctttgg tatttcaggg agacactcca tcacagtcac 180
tactgtcgcc tcagctggga acattgggga ggatggaatc ctgagctgca cttttgaacc 240
tgacatcaaa ctttctgata tcgtgataca atggctgaag gaaggtgttt taggcttggt 300
ccatgagttc aaagaaggca aagatgagct gtcggagcag gatgaaatgt tcagaggccg 360
gacagcagtg ttgtctgata aagtgatagt tggcaatgcc tctttgctgc tgaaaaacgt 420
gcaactcaca gatgctggca cctacaaatg ttatatcatc acttctaaag gcaaggggaa 480
tgctaacctt gagtataaaa ctggagcctt cagcatgccg gaagtgaatg tggactataa 540
tgccagctca gagaccttgc ggtgtgaggc tccccgatgg ttccccagc ccacagtgg 600
ctgggcatcc caagttgacc agggagccaa cttctcggaa gtctccaata ccagcttga 660
gctgaactct gagaatgtga ccatgaaggt tgtgtctgtg ctctacaatg ttacgatcaa 720
caacacatac tcctgtatga ttgaaaatga cattgccaaa gcaacagggg atatcaaagt 780
gacagaatcg gagatcaaaa ggcggagtca cctacagctg ctaaactcaa aggcttctct 840
gtgtgtctct tctttctttg ccatcagctg ggcacttctg cctctcagcc cttacctgat 900
gctaaaataa tgtgccttgg ccacaaaaaa gcatgcaaag tcattgttac aacagggatc 960
tacagaacta tttcaccacc agatatgacc tagttttata tttctgggag gaaatgaatt 1020
catatctaga agtctggagt gagcaaaaa gagcaagaaa caaaaagaag ccaaaagcag 1080
aaggctccaa tatgaacaag ataaatctat cttcaaagac atattagaag ttgggaaaat 1140
```

```

aattcatgtg aactagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag 1200
tgcattccca gatctcaggg acctccccct gcctgtcacc tggggagtga gaggacagga 1260
tagtgcatgt tctttgtctc tgaattttta gttatatgtg ctgtaatgtt gctctgagga 1320
agcccctgga aagtctatcc caacatatcc acatcttata ttccacaaat taagctgtag 1380
tatgtaccct aagacgctgc taattgactg ccacttcgca actcaggggc ggctgcattt 1440
tagtaatggg tcaaagtatt cactttttat gatgcttcca aagggtgcctt ggcttctctt 1500
cccaactgac aaatgccaaa gttgagaaaa atgatacataa ttttagcata aacagagcag 1560
tcggcgacac cgattttata aataaactga gcaccttctt tttaaacaaa caaatgcggg 1620
tttatttctc agatgatgtt catccgtgaa tgggtccaggg aaggaccttt caccttgact 1680
atatggcatt atgtcatcac aagctctgag gcttctcctt tccatcctgc gtggacagct 1740
aagacctcag ttttcaatag catctagagc agtgggactc agctgggggtg atttcgcccc 1800
ccatctccgg gggaaatgtct gaagacaatt ttggttacct caatgagggg gtggaggagg 1860
atacagtgtc actaccaact agtggataaa ggccagggat gctgctcaac ctccaccat 1920
gtacaggacg tctccccatt acaactaccc aatccgaagt gtcaactgtg tcaggactaa 1980
gaaaccttg ttttgagtag aaaagggcct ggaaagaggg gagccaacaa atctgtctgc 2040
ttctcacatt agtcattggc aaataagcat tctgtctctt tggctgctgc ctcagcacag 2100
agagccagaa ctctatcggg caccaggata acatctctca gtgaacagag ttgacaaggc 2160
ctatgggaaa tgctgatgg gattatcttc agcttggtga gcttctaagt ttctttccct 2220
tcattctacc ctgcaagcca agttctgtaa gagaaatgcc tgagtcttag ctcagggttt 2280
cttactctga atttagatct ccagaccctt cctggccaca attcaaatta aggcaacaaa 2340
catatacctt ccatgaagca cacacagact tttgaaagca aggacaatga ctgcttgaat 2400
tgaggccttg aggaatgaag ctttgaagga aaagaatact ttgtttccag ccccttccc 2460
acactcttca tgtgttaacc actgccttcc tggaccttgg agccacggtg actgtattac 2520
atgttggtat agaaaactga ttttagagtt ctgatcgttc aagagaatga ttaaataac 2580
atttct

```

&lt;210&gt; 2

&lt;211&gt; 2070

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

cacagagaga ggcagcagct tgctcagcgg acaaggatgc tgggcgtgag ggaccaaggc 60
ctgccctgca ctggggcctc ctccagccag tgctgaccag ggacttctga cctgctggcc 120
agccaggacc tgtgtgggga ggcctcctc ctgccttggg gtgacaatct cagctccagg 180
ctacaggag accgggagga tcacagagcc agcatgttac aggatcctga cagtgatcaa 240
cctctgaaca gcctcgatgt caaacccctg cgcaaaccct gtatcccat ggagaccttc 300
agaaagggtg ggatcccat catcatagca ctactgagcc tggcgagtat catcattgtg 360
gttgtcctca tcaagggtgat tctggataaa tactacttcc tctgcgggca gcctctccac 420
ttcatcccga ggaagcagct gtgtgacgga gagctggact gtcccttggg ggaggacgag 480
gagcactgtg tcaagagctt ccccgaggg cctgcagtgg cagtcgcct ctccaaggac 540
cgatccacac tgcaggtgct ggactcggcc acagggaact ggttctctgc ctgtttcgac 600
aacttcacag aagctctcgc tgagacagcc tgtaggcaga tgggctacag cagcaaacc 660
actttcagag ctgtggagat tggccagac caggatctgg atgttgttga aatcacagaa 720
aacagccagg agcttcgcat gcggaactca agtgggcct gtctctcagg ctccctggtc 780
tccctgcact gtcttgctg tgggaagagc ctgaagacc cccgtgtggt ggggtgggag 840
gaggcctctg tggattcttg gccttggcag gtcagcatcc agtacgaaa acagcacgct 900
tgtggaggga gcatcctgga cccccactgg gtctcagcg gcagcccact gcttcaggaa 960

```

```

acataccgat gtgttcaact ggaaggtgcg ggcaggctca gacaaactgg gcagcttccc 1020
atccctggct gtggccaaga tcatcatcat tgaattcaac cccatgtacc ccaaagacaa 1080
tgacatcgcc ctcatgaagc tgcagttccc actcacttcc tcaggcacag tcaggcccat 1140
ctgtctgccc ttctttgatg aggagctcac tccagccacc ccactctgga tcattggatg 1200
gggctttacg aagcagaatg gagggaagat gtctgacata ctgctgcagg cgtcagtcca 1260
ggtcattgac agcacacggt gcaatgcaga cgatgcgtac cagggggaag tcaccgagaa 1320
gatgatgtgt gcaggcatcc cggaaggggg tgtggacacc tgccaggggtg acagtgggtg 1380
gcccctgatg taccaatctg accagtggca tgtggtgggc atcgttagct ggggctatgg 1440
ctgcggggggc ccgagcacc caggagtata caccaaggct tcagcctatc tcaactggat 1500
ctacaatgtc tggaaggctg agctgtaatg ctgctgcccc ttgagcagtgc tgggagccgc 1560
ttccttcctg ccctgcccac ctggggatcc cccaaagtca gacacagagc aagagtcccc 1620
ttgggtacac ccctctgccc acagcctcag catttcttgg agcagcaaag ggccctcaatt 1680
cctataagag accctcgag cccagaggcg cccagaggaa gtcagcagcc cttagctcggc 1740
cacacttggt gctcccagca tcccaggag agacacagcc cactgaacaa ggtctcaggg 1800
gtattgctaa gccaaagaag aactttccca cactactgaa tggaagcagg ctgtcttgta 1860
aaagcccaga tcaactgtgg ctggagagga gaaggaaagg gtctgcgcca gccctgtccg 1920
tcttcaccca tcccgaagcc tactagagca agaaaccagt tgtaataata aatgcactgc 1980
cctactgttg gtatgactac cgttacctac tgttgcatg ttattacagc tatggccact 2040
attattaaag agctgtgtaa catctctggc
2070

```

&lt;210&gt; 3

&lt;211&gt; 1709

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

agcagaactca caccagaact acattccctg gcccctgccc tgtgtgcttc tggccaggcc 60
ttgggttgga agtctgaccc gagaaaagga tctgcagaaa atcagactat gggatcactt 120
tgtttgtgca ttgggaatga cattctttcc cccccagga aaacctttgg gactttcaga 180
gacattgtgg ctagccaacc acatggctcag cctcaaagtt gagaggctca gtaacctcc 240
tatccctaga gaattccaaa gtgtggatgt aatttaacta gaaagccatt ggtgactatc 300
tgtgatcctc tggaagtatg ctatgttggt tatactctgc atccaaagcc agagggaacc 360
acaatgacta gtaaaacggt ggtctcaatg cccacttagc ctctgcctct gaatttgacc 420
atagtggcgt tcagctgata gagcgggaag aagaaatatg cattttttat gaaaaataa 480
atatccaaga gaagatgaaa ctaaatggag aaattgaaat acatctactg gaagaaaaga 540
tccaattcct gaaaatgaag attgctgaga agcaaagaca aatttgtgtg acccagaaat 600
tactgccagc caagaggctc ctggatgccg acctagctgt gctccaaatt cagttttcac 660
agtgtacaga cagaattaaa gacctggaga aacagttcgt aaagcctgat ggtgagaata 720
gagctcgctt ccttccaggg aaagatctga cggaaaaaga aatgatcaa aaattagaca 780
agctggaact acaactggcc aagaaggagg agaagctgct ggagaaggat ttcactctatg 840
agcaggctct caggctcaca gacaggctct gcagcaaac tcagggtctgc aagcaggaca 900
cactgctctt agccaagaag atgaatggct atcaaagaag gatcaaaaat gcaactgaga 960
aatgatggc tcttgttgct gagctgtcca tgaaacaagc cctaaccatt gaactccaaa 1020
aggaagtcag ggagaaagaa gacttcatct tcaacttgcaa ttccaggata gaaaaaggtc 1080
tgccactcaa taaggaaatt gagaaagaat gggtgaaagt ccttcgagat gaagaaatgc 1140
acgccttggc catcgctgaa aagtctcagg agttcttggg agcagataat cgccagctgc 1200
ccaatgggtg ttacacaact gcagagcagc gtccgaatgc ctacatocca gaagcagatg 1260
ccactcttcc ttgccaataa ccttatgggt ctttggctcc ttttaaacc agtgaacctg 1320

```

gagccaatat gaggcacata aggaaacctg ttataaagcc agttgaaatc tgaatatgtg 1380  
 aacaaatcca ggcctctcaa ggaaaagact tcaaccaggc ttccttgtag ccacagggtga 1440  
 aaaatgtgag cataatactt ctaatattat tgataagtaa ggtaaccaca attagtcagc 1500  
 aacagagtac aacagggttt ctatttacct accaactact atacctttca tgacgttgaa 1560  
 tgggacatag aactgtccta catTTatgtc aaagtatata tttgaatcgc ttatatTTtc 1620  
 tttttcactc tttatattga gtacattcca gaaatttgta gtaggcaagg tgctataaaa 1680  
 atgcactaaa aataaatctg ttctcaatg 1709

<210> 4

<211> 257

<212> DNA

<213> Homo sapiens

<400> 4

ttaatgggta agtatttttt atatgcttta gctatagcta aagaaaactg atacttaaca 60  
 aagttgaata gtattattca ctgggtgctcc taaaatattg tttttcagtg taaaatatgc 120  
 atatcttcta tatttaatat gaaagtcttg aaatgtatca gacagaaggg gatttcagtt 180  
 tgcaaataat gagcaatgta gcaattttta cacatttcat aaatatatat tttgtcattg 240  
 gtggagagca ccatttg 257

<210> 5

<211> 359

<212> DNA

<213> Homo sapiens

<400> 5

gcctgagagc acttagcggt catgagtgtc cccaccatgg cctggatgat gcttctcctc 60  
 ggactccttg cttatggatc aggtcaggga gtggattctc agactgtggt gacccaagag 120  
 ccacgttat cagtgtcccc tggagggaca gtcacactca ctgtggcctt ggctcttgac 180  
 tcagtctcta ctaatttctt cccacctgg taccagcaga cccagggcca ggctccacgc 240  
 acgctcatct acagcacaag cactcgctct tctgggggtcc ctgatcgttt ctctgggtcc 300  
 atccttggga acaaagctgc cctcaccatt acggggggccc aggcagatga tgaatctga 359

<210> 6

<211> 1372

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (6)

<220>

<221> unsure

<222> (9)

<400> 6

ccttanagnc ttggttgcca aacagaatgc ccatatccgt cttacttggt aggaagcttg 60

```

ccttgggagc cctctgctgg cctcctgaa gctaacaggg gcgagtgtc ggtggtttac 120
aaattgcctc catgcagact atgaaactgt tcagcctgct atagttagat ctctggcact 180
ggcccaggag gtcttgacaga tttgcagatc aaggagaacc caggagtttc aaagaagcgg 240
ctagtaaagg tctctgagat ccttgcaacta gctacatcct cagggtagga ggaagatggc 300
ttccagaagc atgcggctgc tctattgct gagctgctg gccaaaacag gagtctggg 360
tgatatcatc atgagacca gctgtgctcc tgggatggtt ttaccacaag tccaattgct 420
atggttactt caggaagctg aggaactggt ctgatgccga gctcgagtgt cagtcttacg 480
gaaacggagc ccacctggca tctatcctga gtttaaagga agccagcacc atagcagagt 540
acataagtgg ctatcagaga agccagccga tatggattgg cctgcacgac ccacagaaga 600
ggcagcagtg gcagtggatt gatggggcca tgtatctgta cagatcctgg tctggcaagt 660
ccatgggtgg gaacaagcac tgtgctgaga tgagctccaa taacaacttt ttaacttgga 720
gcagcaacga atgcaacaag cgccaacact tcctgtgcaa gtaccgacca tagagcaaga 780
atcaagattc tgctaactcc tgcacagccc cgtcctcttc ctttctgcta gcctggctaa 840
atctgctcat tatttcagag gggaaaccta gcaaactaag agtgataagg gccctactac 900
actggctttt ttaggcttag agacagaaac ttttagcattg gcccagtagt ggcttctagc 960
tctaaatgtt tgccccgcca tccctttcca cagtatcctt cttccctcct ccctgtctc 1020
tggtgtgtc gagcagtcta gaagagtga tctccagcct atgaaacagc tgggtctttg 1080
gccataagaa gtaaagattt gaagacagaa ggaagaaact caggagtaag cttctagccc 1140
ccttcagctt ctacaccctt ctgccctctc tccattgcct gcacccacc ccagccactc 1200
aactcctgct tgtttttcct ttggccatgg gaaggtttac cagtagaatc cttgctaggt 1260
tgatgtgggc catacattcc ttttaataaac cattgtgtac ataagaggtt gctgtgttcc 1320
agttcagtaa atggtgaatg tggaaaagtg aaataagacc aagaaataca aa 1372

```

&lt;210&gt; 7

&lt;211&gt; 291

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (277)

&lt;400&gt; 7

```

agaatggtag tagtaagaag aagaaaaata gaggatctga atgtattttg aaggtagagt 60
ccactggact tagagatgga ttgaatgtgg aagattaagg aaagggagaa atgaaagata 120
gtcttaggtt tcatcttcag atgactgggt gaacagcagt gttctttgct aagatgggga 180
agactaggga aaagagccag ttctgtattg agcatattat atttaagaca atcccatctg 240
ggtccaaaga caatgttgat ttttttctt agatacntgc cttttagacc t 291

```

&lt;210&gt; 8

&lt;211&gt; 1275

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (410)



&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (728)..(756)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (957)

&lt;400&gt; 8

```

attctagaac atatgtataa gctaaaaaca gtattttact cagatcagta gttatcgtgt 60
ctatcagcta taaaaaaaaat caactgccag ccaagaactt taaaacttta agctgtgtat 120
tatagaaccg ttttgtgtag cattggaata ttgtccattt tgtaagtcac tgtgaatgtt 180
cttaattatc agcttgaagg tatttttcta ttaaaagttg acattgaaga acctaagtgg 240
atgatgggat ttggggccag tagtgaaagt atgtttcctc taaaatattt ccctaaacag 300
tgggtatacat gggtatttta ttatgagatt tgtatatgtt ctgtgtttct ctgtgaacaa 360
tgtttcagtc tctctgtcac catatgtaag gggaagtcca caaatatagn actacattgc 420
acaaaactaa aattgttaat tacaagaaaa tataggtgct taccttttga aggtttatta 480
atacatatgg ttgtcacaa acgtatatat gataaatggg gtacatatac agatgtttat 540
ggtgtataaa tttttctata cccaattaga attatcttcc tgattcttta ttcaataaca 600
tgctaattcc tcttctatgt tctatagtga cagaatgcta acttttctta taccctggca 660
gaggacagag gagtctggtc taggatgggg aactgaattt ttgaacgaaa aggaaagaga 720
aaggatgnnn nnnnnnnnnn nnnnnnnnnn nnnnnntaat gtttcttagt ctttttgatt 780
ggccatttga acagtctaca agtttaacgt tatttccagt gaagtaggat ggctgacctt 840
gcaatacatg tttcttcaaa agggtaaaca tgcttttagt acctaaagct aaattttgta 900
catttgacat caggggtgtt ataagtactg cacttaatac aaagctattt ctcaatngtg 960
ttatttttga gacaaatttt tcttcaccat taacttcttg ttggtagctt tttgttttgt 1020
aaaaattgag agatggcaat gcttatctca accagattat ccatctgcag aattaaggta 1080
tgcaactggt aaataaaaga caaatgtccc agtttgtctt tctcaacctt tgagttctta 1140
acctttgagt taaaacctag tctaaatagt gggaatgtct tggtttacag taagggtttc 1200
ttgggaagga tcttggtttt gtgatctatt tgtgaattaa ggagtagatg ttaaccatta 1260
ttttatagat aagtg 1275

```

&lt;210&gt; 9

&lt;211&gt; 2479

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```

gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaacctat ggataccaac 120
cggaataccc ctatcccgcg cagcccactg tgggtccccc tgtctacgag gtgcatccgg 180
ctcagtacta cccgtccccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
accccgctcg ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
agaaagcact gtgcatcacc ttgaccctgg ggaccttctt cgtgggagct gcgctggccg 360
ctggcctact ctggaagttc atgggcagca agtgcctcaa ctctgggata gagtgcgact 420
cctcaggtac ctgcatcaac cctctaaact ggtgtgatgg cgtgtcacac tgccccggcg 480
gggaggacga gaatcggtgt gtctgcctct acggaccaaa ctcatcctt cagatgtact 540
catctcagag gaagtctcgt caccctgtgt gccaaagacg ctggaacgag aactacgggc 600

```

gggcgccctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660  
atgacagcgg atccaccagc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720  
ataaaaaact gtaccacagt gatgcctgtt cttcaaaagc agtggtttct ttacgctgtt 780  
tagcctgagg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840  
cgctcccggg ggctggccc tggcaggtca gcctgcacgt ccagaacgtc cacgtgtgcg 900  
gaggctccat catcaccccc gagtggatcg tgacagccgc ccactgctg gaaaaacctc 960  
ttaacaatcc atggcatttg acggcatttg cggggatttt gagacaatct ttcattgttct 1020  
atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080  
agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gacctagtga 1140  
aaccagtgtg tctgcccac ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200  
ccgggtgggg ggccaccgag gagaaaggga agacctcaga agtgctgaac gctgccaagg 1260  
tgcttctcat tgagacacag agatgcaaca gcagatatgt ctatgacaac ctgatcacac 1320  
cagccatgat ctgtgccggc ttctgcagg ggaacgtcga ttcttgccag ggtgacagtg 1380  
gagggcctct ggtcacttcg aacaacaata tctggtggct gataggggat acaagctggg 1440  
gttctggctg tgccaaagct tacagaccag gagtgtagc gaatgtgatg gtattcacgg 1500  
actggattta tcgacaaatg aaggcaaagc gctaattcac atggtcttcg tcttgacgt 1560  
cgttttacaa gaaaacaatg gggctgggtt tgcttccccg tgcatgattt actcttagag 1620  
atgattcaga ggtcacttca tttttattaa acagtgaact tgtctggctt tggcactctc 1680  
tgccatactg tgcaggctgc agtggctccc ctgccagcc tgctctccct aaccttctgt 1740  
ccgcaagggg tgatggccgg ctggttggtg gcaactggcg tcaattgttg aaggaagagg 1800  
gttgaggct gccccattg agatcttct gctgagctct ttccagggg caattttgga 1860  
tgagcatgga gctgtcactt ctgagctgct ggatgacttg agatgaaaaa ggagagacat 1920  
ggaaagggag acagccaggt ggcacctgca gcggctgcc tctggggcca cttggtagt 1980  
tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040  
gatggtggcc agaaataaag ggaccagccc ttcattgggt gtgacgtggt agtcacttgt 2100  
aaggggaaca gaaacatttt tgttcttatg ggtgagaat atagacagt cccttggtgc 2160  
gagggaaagc attgaaaagg aacttgccct gagcactcct ggtgcaggtc tccacctgca 2220  
cattgggtgg ggctcctggg agggagactc agccttctc ctcatctcc ctgacctgc 2280  
tcttagcacc ctggagagt aatgcccctt ggtccctggc agggcgccaa gtttggcacc 2340  
atgtcggcct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400  
atgtcagtt taaggtagac tgtttccatg ttatgtttct acacattgat ggtggtgacc 2460  
ctgagttcaa agccatctt 2479

&lt;210&gt; 10

&lt;211&gt; 576

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

ttcaaagaca tattagaagt tgggaaaata attcatgtga actagacaag tgtgttaaga 60  
gtgataagta aaatgcacgt ggagacaagt gcatccccag atctcaggga cctccccctg 120  
cctgtcacct ggggagttag aggacaggat agtgcattgt ctttgtctct gaatttttag 180  
ttatatgtgc tgtaatgttg ctctgaggaa gccctggaa agtctatccc aacatatoca 240  
catcttatat tccacaaatt aagctgtagt atgtacccta agacgtgct aattgactgc 300  
cacttcgcaa ctgagggcg gctgcatttt agtaattgggt caaatgattc actttttatg 360  
atgcttccaa aggtgccttg gcttctcttc ccaactgaca aatgccaaag ttgagaaaaa 420  
tgatcataat ttttagcataa acagagcagt cggcgacacc gattttataa ataaactgag 480  
caccttcttt ttaaacaac aaatgcgggt ttatttctca gatgatgttc atccgtgaat 540

gggccagggga agggacctttc accttgacta tatggc

576

<210> 11

<211> 890

<212> DNA

<213> Homo sapiens

<400> 11

```

caagctctga ggcttctcct ttccatcctg cgtggacagc taagacctca gttttcaata 60
gcatctagag cagtgggact cagctggggt gatttcgccc cccatctccg ggggaatgtc 120
tgaagacaat tttggttacc tcaatgaggg agtggaggag gatacagtgc tactaccaac 180
tagtgataa aggccagggga tgctgctcaa cctcctacca tgtacagggg cgtctcccca 240
ttacaactac ccaatccgaa gtgtcaactg tgtcaggact aagaaaccct ggttttgagt 300
agaaaagggc ctggaaagag gggagccaac aaatctgtct gcttcctcac attagtcatt 360
ggcaaataag cattctgtct ctttggctgc tgcctcagca cagagagcca gaactctatc 420
gggcaccagg ataacatctc tcagtgaaca gagttgacaa ggcctatggg aaatgcctga 480
tggtgattatc ttcagcttgt tgagcttcta agtttctttc ccttcattct accctgcaag 540
ccaagttctg taagagaaat gcttgagttc tagctcaggt tttcttactc tgaatttaga 600
tctccagacc cttcctggcc acaattcaaa ttaaggcaac aaacatatac cttccatgaa 660
gcacacacag acttttgaaa gcaaggacaa tgactgcttg aattgaggcc ttgaggaatg 720
aagctttgaa ggaaaagaat actttgtttc cagccccctt cccacactct tcatgtgtta 780
accactgcct tcctggacct tggagccacg gtgactgtat tacatgttgt tatagaaaac 840
tgatttttaga gttctgatcg ttcaagagaa tgattaaata tacatttcct 890

```

<210> 12

<211> 406

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (30)

<220>

<221> unsure

<222> (248)

<220>

<221> unsure

<222> (383)

<400> 12

```

gtgaatgtgg actataatgc cagctcagan accttgcggt gtgaggctcc ccgatgggtc 60
ccccagccca cagtgggtctg ggcattccaa gttgaccagg gagccaactt ctcggaagtc 120
tccaataacca gctttgagct gaactctgag aatgtgacca tgaaggttgt gtctgtgctc 180
tacaatgtta cgatcaacaa cacatactcc tgtatgattg aaaatgacat tgccaaagca 240
acaggggnta tcaaagtgac agaatcggag atcaaaaaggc ggagtcacct acagctgcta 300
aactcaaagg cttctctgtg tgtctcttct ttctttgcca tcagctgggc acttctgcct 360

```

ctcagccctt acctgatgct aanataatgt gccttggcca caaaaa

406

&lt;210&gt; 13

&lt;211&gt; 462

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

```

ggaaggcagc ggcagctcca ctcagccagt acccagatac gctgggaacc ttccccagcc 60
atggcttccc tggggcagat cctcttctgg agcataatta gcatcatcat tattctggct 120
ggagcaattg cactcatcat tggctttggt atttcagga gacactccat cacagtcact 180
actgtgcct cagctgggaa cattggggag gatggaatcc tgagctgcac ttttgaacct 240
gacatcaaac tttctgatat cgtgatacaa tggctgaagg aaggtgtttt aggcttggtc 300
catgagttca aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagaggccgg 360
acagcagtggt ttgctgatca agtgatagtt ggcaatgcct ctttgcggct gaaaaacgtg 420
caactcacag atgctggcac ctacaaatgt tatatcatca ct

```

462

&lt;210&gt; 14

&lt;211&gt; 272

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

```

gcagcttgct cagcggacaa ggatgctggg cgtgaggac caaggcctgc cctgcactcg 60
ggcctcctcc agccagtgt gaccaggac ttctgacctg ctggccagcc aggacctgtg 120
tggggaggcc ctctgctgc cttggggtga caatctcagc tccaggctac agggagaccg 180
ggaggatcac agagccagca tggatcctga cagtgatcaa cctctgaaca gcctcgtcaa 240
ggtgattctg gataaatact acttcctctg cg

```

272

&lt;210&gt; 15

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu  
1 5 10 15

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val  
20 25 30

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro  
35 40 45

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val  
50 55 60

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys

65	70	75	80
Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val			
	85	90	95
Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys			
	100	105	110
Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn			
	115	120	125
Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp			
	130	135	140
Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met			
	145	150	155
Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp			
	165	170	175
Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn			
	180	185	190
Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser			
	195	200	205
Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys			
	210	215	220
Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg			
	225	230	235
Cys Leu Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile			
	245	250	255
Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser			
	260	265	270
Leu His Val Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro			
	275	280	285
Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn			
	290	295	300
Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met			
	305	310	315
Phe Tyr Gly Ala Gly Tyr Gln Val Gln Lys Val Ile Ser His Pro Asn			

325

330

335

Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln  
340 345 350

Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn  
355 360 365

Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp  
370 375 380

Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala  
385 390 395 400

Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr  
405 410 415

Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly  
420 425 430

Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser  
435 440 445

Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly  
450 455 460

Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe  
465 470 475 480

Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly  
485 490

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C07K 16/8

US CL : 435/6, 7.1, 7.92; 530/387.1, 388.85

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 7.92; 530/387.1, 388.85 -

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
SEQ ID NO's 1-5 and 9-14Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Medline, CAPLUS, GenEmbl, N-Geneseq, USPATFULL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,939,258 A (CROCE et al) 17 August 1999, see col. 3, lines 1-22.	1-3
---P		-----
Y		4,5
X	US 5,733,748 A ( YU et al) 31 March 1998, see abstract.	1-3
-----		-----
Y		4, 5

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 22 NOVEMBER 1999	Date of mailing of the international search report 07 FEB 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer LARRY HELMS Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PAOLONI-GIACOBNO et al. Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCR Domains and Maps to 21q22.3. Genomics. 1997, Vol. 44, pages 309-320, especially page 311.	1-9

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-9

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)\*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19655

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

Group I, claim(s) 1-9, drawn to an in vitro method for diagnosing the presence of cancer by measuring the CSG levels in a patient with an antibody against CSG.

Group II, claim(s) 10-11, drawn to a method of in vivo imaging a selected cancer by administering an antibody with a paramagnetic ion or radioisotope label to the patient.

Group III, claim(s) 12-13, drawn to a method of in vivo treating a cancer in a patient comprising administering an antibody conjugated to a cytotoxic agent.

The inventions listed as Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The method of Group I recites the special technical feature of an in vitro diagnostic method to measure CSG levels that are not found in Groups II and III. The method of Group II recites the special technical features of an in vivo imaging method that is not found in Groups I and III. The method of Group III recites the special technical feature of in vivo treating a cancer using a cytotoxic agent that is not found in Groups I and II. Therefore, inventions of Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1.